Redenlab supporting PTC Theraputics in Global Phase 3 Clinical Trial

Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich #Ataxia.

The Phase 3 MOVE-FA trial is an 18-month parallel arm, placebo-controlled study evaluating vatiquinone versus placebo in approximately 110 children and young adults with FA. The primary endpoint is the change from baseline in the modified Friedreich ataxia rating scale (mFARS), with key secondary endpoints assessing ambulation and activities of daily living (incl #speech). This endpoint strategy was developed in consultation with both the FDA and European Medicines Agency. The study will include sites in the U.S., E.U., Australia and Latin America.

Click here for more details.

Related Post

  • Posted on 27 April, 2023
    Redenlab have been featured in the Huberman Lab Podcast for their study on “Adults with a history of recreational cannabis...
    • Posted on 30 March, 2023
      L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
      • Posted on 30 March, 2023
        Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision...